June 2, 2009

FOR IMMEDIATE RELEASE

Arbor Pharmaceuticals Announces the Launch of ZINOTIC® ES – A New Extra Strength Product for the Treatment of Acute Otitis Externa

Raleigh, NC – Arbor Pharmaceuticals (“Arbor”), a specialty pharmaceutical company focused exclusively on pediatric medicine, announced today that the company has launched ZINOTIC ES as a new treatment option for Acute Otitis Externa (AOE). ZINOTIC ES is an extra strength formulation of original ZINOTIC intended to provide children suffering from AOE with a greater degree of pain relief and skin protection. ZINOTIC ES is Arbor Pharmaceuticals’ fourth product launch in the U.S. and is now available by prescription from retail pharmacies across the U.S.

AOE or “swimmer’s ear” is a common childhood infection of the ear canal characterized by intense pain and inflamed, damaged skin. Children are most susceptible to AOE, and swimming is the most common predisposing factor for acquiring the infection. When treating AOE there are three main goals to address including treating the infection, relieving the pain and restoring the integrity of the lining of the ear canal. ZINOTIC is the only family of products that addresses the three AOE treatment goals. ZINOTIC ES contains the maximum dose of pramoxine and a higher level of zinc acetate to enable greater pain relief and skin protection while treating the infection without an antibiotic.

“ZINOTIC has become an important AOE treatment option since its introduction, and new ZINOTIC ES will be a welcome addition to the ZINOTIC franchise as it further addresses the three AOE treatment goals with its enhanced, extra strength formulation,” according to Jarrett Disbrow, President and CEO of Arbor Pharmaceuticals. “The launch of ZINOTIC ES demonstrates the company’s ongoing dedication to enhancing pediatric medicine. Arbor will continue to build its portfolio of pediatric pharmaceuticals focused on providing novel prescription products for the most common pediatric illnesses.”

ZINOTIC ES is being promoted to U.S. pediatricians by Arbor Pharmaceuticals’ sales force and via partner companies in select regions of the U.S. For more information about ZINOTIC ES, visit www.zinotic.com. The most common side effects of pramoxine (contained in ZINOTIC ES) include redness, irritation, swelling, burning, stinging, pain or dryness at the affected area.

About Arbor Pharmaceuticals
Arbor Pharmaceuticals is a Raleigh, North Carolina-based specialty pharmaceutical company focused exclusively on the growing pediatric market. The company is well positioned to become the leading pediatrics-focused pharmaceutical company by actively licensing, developing and commercializing late-stage products for common pediatric conditions. The company currently focuses on nonantibiotic products for ear infections including ZINOTIC for acute otitis externa, XYLAREX for the dietary management of recurrent ear infections and NEOTIC for acute otitis media. Arbor is also building a pipeline of other promising products for the most common pediatric illnesses. To learn more about Arbor Pharmaceuticals, visit www.arborpharma.com or send email inquiries to info@arborpharma.com.

February 26, 2009

FOR IMMEDIATE RELEASE

Arbor Pharmaceuticals Announces the Launch of XYLAREX™ - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children

Raleigh, NC – Arbor Pharmaceuticals, a specialty pharmaceutical company focused exclusively on pediatric medicine, announced today that the company has launched XYLAREX - a first-in-class nonantibiotic for the dietary management of recurrent acute otitis media (middle ear infections). XYLAREX is a novel oral solution intended to be administered daily to reduce the number of ear infections children experience. The primary ingredient in XYLAREX has also been shown to reduce the amount of antibiotics prescribed to children affected by middle ear infections. XYLAREX can be administered to children as young as six months of age.

Acute Otitis Media (AOM) is the most common bacterial illness of childhood and the primary reason antibiotics are prescribed for children in the U.S. Recurrent AOM affects millions of U.S. children each year, and children suffering from repeated, painful ear infections are frequently exposed to numerous courses of antibiotics at a young age. With repeated antibiotic exposure there is an increased risk of developing bacterial resistance, which the Centers for Disease Control and Prevention (CDC) call one of the world’s most pressing health concerns.

“Until now there have been limited options for managing children with recurrent acute otitis media. Pediatricians and otolaryngologists alike see many children with recurrent ear infections who have to been subjected to countless antibiotic courses and – in severe cases – may require ear tube placement to alleviate symptoms. Parents and clinicians are looking for new options for these children. A novel, non-drug product like XYLAREX is an important new option for managing children with recurrent AOM in order to reduce their infections and decrease their need for antibiotics,” says Mark Mehle, M.D., a practicing ear, nose, and throat physician in Cleveland, Ohio.

According to Jarrett Disbrow, President and CEO of Arbor Pharmaceuticals, “XYLAREX is a very important product as it represents a first-in-class non-drug therapy with the potential to positively impact the lives of millions of children suffering from recurrent ear infections. Arbor is firmly dedicated to health of children, and XYLAREX will be a significant addition for the management of common ear infections.”

XYLAREX is available by prescription and can be obtained from retail pharmacies across the U.S. XYLAREX is being introduced to U.S. pediatricians by Arbor Pharmaceuticals’ specialty sales force. XYLAREX is Arbor Pharmaceuticals’ third product introduction since the company initiated commercial operations less than two years ago.

January 7, 2009

Arbor Pharmaceuticals Announces Closing of Series A Financing and Initial Deployment of the Company’s Pediatric Sales Force
 
Raleigh, NC – Arbor Pharmaceuticals (“Arbor”), an emerging specialty pharmaceutical company focused exclusively on pediatric medicine, announced today that the company recently closed its Series A financing. This latest round of investment capital will support the launch of Arbor’s third product and facilitate continued growth of the company and its current and pipeline products. The Series A funding was participated in by several new investors in addition to the company’s original investment group. Since the founding of Arbor in 2006 the company has launched two novel prescription products for ear infections (Zinotic® and Neotic®) and is developing a pipeline of unique nonantibiotic products for common pediatric illnesses.
 
“This new round of funding will allow the company to continue on its significant growth trajectory by introducing new and important treatment options for children. We are grateful to the company’s investors for recognizing the significant value that Arbor has created as an emerging leader in pediatric pharmaceuticals. Arbor is well positioned to continue to introduce important and novel pediatric treatment options and further establish Arbor as a leader in the growing pediatric pharmaceuticals market,” says Jarrett Disbrow, President & CEO of Arbor.
 
In addition to completing the Series A financing Arbor has recently deployed a specialty sales force focused on promoting the company’s products to pediatricians across the United States. The company also has a promotional agreement with a partner company to promote Arbor’s products in several markets. Arbor’s products are now being promoted in more than 25 major U.S. metropolitan areas, and the company plans to expand its sales force in the coming months.
 
About Arbor Pharmaceuticals
Arbor Pharmaceuticals is a Raleigh, North Carolina-based specialty pharmaceutical company focused exclusively on the growing pediatric market. Arbor actively licenses, develops and commercializes pediatric products initially focused on nonantibiotic products for the treatment of various ear infections and currently markets two patented products, ZINOTIC® and NEOTIC®. The company intends to become the leading pharmaceutical company within pediatrics by developing and commercializing a robust pipeline of late-stage products for common pediatric conditions. Arbor will launch a novel treatment option for recurrent middle ear infections in early 2009.

October 13, 2008

Arbor Pharmaceuticals Launches NEOTIC™ – A New Prescription Treatment for the Painful Symptoms of Common Middle Ear Infections

Raleigh, NC – Arbor Pharmaceuticals announced today that the company’s second prescription product, NEOTIC™, has been launched in the U.S. and is now available for the treatment of pain and inflammation associated with middle ear infections (also called Acute Otitis Media, or AOM). Acute otitis media represents the second most common infection among children in the US and the number one reason antibiotics are prescribed by U.S. pediatricians. AOM accounts for almost 25 million physician office visits in the U.S. each year resulting in over 20 million antibiotic prescriptions. NEOTIC™ is a novel, patented non-antibiotic otic (ear) prescription treatment that combines a unique combination of active ingredients with a convenient dual-unit package for children. NEOTIC™ is indicated to relieve pain and reduce inflammation associated with acute otitis media and as an adjunct to oral antibiotic treatment for acute otitis media.
 
“The launch of NEOTIC™ represents another important milestone for Arbor as it demonstrates the Company’s continuing commitment to provide novel therapeutic options for significant pediatric conditions. NEOTIC™ is a unique new product for pediatricians and offers significant value to healthcare professionals and the millions of children affected with AOM” says Jarrett Disbrow, President & Chief Executive Officer of Arbor Pharmaceuticals, Inc.
 
Arbor Pharmaceuticals has partnered with an established specialty pharmaceutical company to promote NEOTIC™ to physicians across the U.S. NEOTIC™ is available by prescription only through retail pharmacies throughout the U.S. For more information about NEOTIC™, please visit www.arborpharma.com. Serious side effects are unlikely with NEOTIC™. Patients may experience burning, stinging, redness and/or new pain in or around the ears.
 
About Arbor Pharmaceuticals
Arbor Pharmaceuticals is a Raleigh, North Carolina based specialty pharmaceutical company focused on the licensing, development, and commercialization of products for pediatricians. Founded in 2006, Arbor actively identifies and licenses unique, patent-protected therapies proven to effectively treat common pediatric illnesses. Arbor Pharmaceuticals collaborates with pharmaceutical development companies and established promotional partners in the pharmaceutical industry to develop and market their products in order to serve the needs of pediatricians throughout the US. To learn more about Arbor Pharmaceuticals, visit www.arborpharma.com or send email inquiries to info@arborpharma.com.

February 18, 2008

Arbor Pharmaceuticals, Inc. Announces Agreement with Accentia Biopharmaceuticals, Inc. to Launch Company’s Second Pediatric Treatment
 
Companies will co-promote NEOTIC™ to pediatricians and ENTs throughout US
 
Raleigh, NC, February 18, 2008 - Arbor Pharmaceuticals, Inc. announced that the company has entered into a sales and marketing agreement with Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) to launch and promote the company’s second prescription product throughout the US. NEOTIC™, Arbor’s patented prescription ear medication, will treat the pain and inflammation associated with middle ear infections and will be promoted by Accentia’s US-based specialty sales force to pediatricians and ENTs. This sales and marketing agreement is Arbor Pharmaceuticals’ second promotional collaboration with Accentia and marks another important milestone in the company’s growth plan. In 2007 Arbor successfully launched its first product - ZINOTIC® - for swimmer’s ear and has demonstrated significant sales growth since its introduction.
 
"Arbor Pharmaceuticals is very pleased to be working with Accentia Biopharmaceuticals to bring NEOTIC™ to the market. Accentia is the ideal partner for Arbor as they are an established specialty pharmaceutical company with a strong orientation toward those physicians who treat the majority of ear infections in the US. We are confident that this collaboration will be beneficial to both companies and will serve to introduce an important new product to pediatricians and ENTs for the millions of children that suffer from acute otitis media," says Jarrett Disbrow, President and Chief Executive Officer of Arbor Pharmaceuticals. Accentia Biopharmaceuticals also announced the NEOTIC™ collaboration. Accentia Chairman and CEO Frank O’Donnell, Jr., MD noted that “Accentia continues to build its specialty pharmaceuticals sales and marketing division with the addition of NEOTIC™. This is an important agreement for both companies as we both continue to execute on our business plans.”
 
About Arbor Pharmaceuticals
Arbor Pharmaceuticals is a Raleigh, North Carolina based specialty pharmaceutical company focused on the licensing, development, and commercialization of products for pediatricians. Founded in 2006, Arbor actively identifies and licenses unique, patent-protected therapies proven to effectively treat common pediatric illnesses. Arbor Pharmaceuticals collaborates with pharmaceutical development companies and established promotional partners in the pharmaceutical industry to develop and market their products in order to serve the needs of pediatricians throughout the US. To learn more about Arbor Pharmaceuticals, visit www.arborpharma.com or send email inquiries to info@arborpharma.com.
 
About Accentia Biopharmaceuticals
Accentia Biopharmaceuticals, Inc. and its subsidiaries is a vertically integrated biopharmaceutical company focused on the development and commercialization of drug candidates that are in late-stage clinical development and typically are based on active pharmaceutical ingredients that have been previously approved by the FDA for other indications. Usually these drug candidates can access the accelerated 505(b)(2) regulatory approval pathway, which is generally less time-consuming and less expensive than the typical 505(b)(1) pathway that must be used for new chemical entities. For further information, visit the company web site at www.accentia.net.

October 10, 2007

Arbor Pharmaceuticals Announces Collaboration with Campbell University Pharmaceutical Sciences Institute On Company’s Latest Pediatric Treatment
 
Raleigh, NC – Arbor Pharmaceuticals, Inc. announced today the company has entered into an agreement with Campbell University’s Pharmaceutical Sciences Institute to develop Arbor’s latest product. Through this collaboration, Campbell University’s experts in pharmaceutical product development will initiate a program to develop a novel formulation for ear infections in children. This agreement represents the first such collaboration between Arbor and Campbell, and the development project is currently underway.
 
“Arbor is pleased to be working with Campbell’s Pharmaceutical Sciences Institute on this important product development project. By initiating this development work on our second product, Arbor continues to expand our pediatric product portfolio aimed at treating the most common childhood illnesses. With Campbell’s development capabilities and pharmaceutical industry expertise, we are confident this project will help to bring another important product to pediatricians and their patients,” says Jarrett Disbrow, President & Chief Executive Officer of Arbor Pharmaceuticals, Inc.
 
According to Dr. William Stagner, PhD, the Director of Campbell University’s Pharmaceutical Sciences Institute, “this pharmaceutical development project will leverage Campbell’s unique in-house expertise and deliver real clinical value in assisting this growing specialty pharmaceutical company. Campbell is glad to have Arbor as a partner, and we look forward to bringing our collective industry and academic experiences to Arbor Pharmaceuticals as they bring another therapy to market.”
 
About Arbor Pharmaceuticals
Arbor Pharmaceuticals is a Raleigh, North Carolina based specialty pharmaceutical company focused on the licensing, development, and commercialization of products for pediatricians. Founded in 2006, Arbor actively seeks out unique, patent-protected therapies proven to effectively treat common pediatric illnesses. Arbor Pharmaceuticals collaborates with pharmaceutical development companies and established promotional partners in the pharmaceutical industry to develop and market their products in order to serve the needs of pediatricians throughout the US. To learn more about Arbor Pharmaceuticals, visit www.arborpharma.com or send email inquiries to info@arborpharma.com.
 
About Campbell University Pharmaceutical Sciences Institute
CUPSI is a pharmaceutical contracting organization, which provides quality research, development and small-scale production services at a competitive price to the pharmaceutical and biotechnology industries. CUPSI functions under the Campbell University system within the Pharmacy Research Facility. Campbell students with a major in Pharmaceutical Sciences are provided with a hands-on approach to education, preparing them as a future workforce in the pharmaceutical industry.

September 26, 2007

Arbor Pharmaceuticals Launches ZINOTIC™ – A Novel Treatment Developed to Relieve the Pain of Outer Ear Infections While Eliminating Infection and Protecting the Skin

Raleigh, NC – Arbor Pharmaceuticals announced today that the company’s first product, ZINOTIC™, has recently been launched in the US and is now available to healthcare practitioners to prescribe for their patients suffering from common outer ear infections. ZINOTIC™ is a novel ear solution that combines chloroxylenol, pramoxine and zinc acetate and is indicated for the treatment of acute otitis externa, or AOE, which is also referred to as swimmer’s ear. ZINOTIC™ combines three unique medications in a patented ear solution. Each component of ZINOTIC™ is important to help decrease symptoms and advance the healing process. Because children are most often affected by outer ear infections having all three medicines in a single topical solution delivers a high level of convenience to the parents and patients.
 
According to Dr. Jeffrey DeWester, a practicing physician and Arbor’s Medical Director, “Ear infections are a very common problem and one of the biggest reasons that a child visits a doctor. Parents bring their child to the doctor because their infected ear is in great pain; touching the ear can bring the child to tears. ZINOTIC™ was developed to help rapidly relieve pain while simultaneously eradicating infection and helping to heal the damaged skin inside the ear. Together, these unique properties offer a real advantage for patients and parents.” Dr. DeWester further commented, “The recently published AOE clinical practice guideline supports the position of a product like ZINOTIC™ in therapy particularly with the incorporation of an effective pain reliever and a non-antibiotic agent that addresses the underlying infection.”
 
“The launch of ZINOTIC™ represents a very important milestone for Arbor as it demonstrates the company’s commitment to provide novel therapeutic options for pediatricians and their patients. More importantly, we believe that ZINOTIC™ will be an important treatment option for children suffering from AOE as ZINOTIC™ is the only treatment that effectively addresses the three goals of AOE therapy - pathogen eradication, pain relief and protecting the ear canal skin” states Jarrett
Disbrow, President & Chief Executive Officer of Arbor Pharmaceuticals, Inc. Arbor Pharmaceuticals has partnered with an established specialty pharmaceutical company to distribute and promote ZINOTIC™ to key pediatricians and otolaryngologists (ENTs) across the U.S. ZINOTIC™ is available by prescription only through retail pharmacies across the U.S. For more information about ZINOTIC™, please visit www.zinotic.com.
 
The most common side effects of pramoxine (contained in ZINOTIC™) include redness, irritation, swelling, burning, stinging, pain or dryness at the affected area. Treatment with ZINOTIC™ should not be continued for longer than ten days and the source of infection and/or inflammation or sensitization evaluated to determine whether therapy should be changed.
 
About Arbor Pharmaceuticals
Arbor Pharmaceuticals is a Raleigh, North Carolina based specialty pharmaceutical company focused on the licensing, development, and commercialization of novel products for pediatricians. Founded in April 2006, Arbor actively seeks out unique, patent-protected therapies proven to effectively treat the most common pediatric illnesses. ZINOTIC™ is the first commercialized product from Arbor Pharmaceuticals, and the company is currently licensing and developing additional products for significant pediatric conditions. Arbor Pharmaceuticals collaborates with pharmaceutical development companies and established promotional partners in the pharmaceutical industry to develop and market their products in order to serve the needs of pediatricians throughout the US.
 
To learn more about Arbor Pharmaceuticals, visit www.arborpharma.com or send email inquiries to info@arborpharma.com.